A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Doravirine, Lamivudine, and Tenofovir Disoproxil (DELSTRIGO)

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2018-07-20
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$92.91/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$92.91
Across all dosage forms in distribution.
Highest NADAC
$92.91
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Doravirine, Lamivudine, and Tenofovir Disoproxil used for?

Doravirine, Lamivudine, and Tenofovir Disoproxil is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Doravirine, Lamivudine, and Tenofovir Disoproxil?

No. Doravirine, Lamivudine, and Tenofovir Disoproxil is brand-only with no generic equivalents currently in market.

How much does my plan pay for Doravirine, Lamivudine, and Tenofovir Disoproxil?

Across 329 Part D plans, Doravirine, Lamivudine, and Tenofovir Disoproxil averages $92.91/unit (NADAC). Lowest available: $92.91/unit. Highest in distribution: $92.91/unit.

Is Doravirine, Lamivudine, and Tenofovir Disoproxil on the FDA shortage list?

No. Doravirine, Lamivudine, and Tenofovir Disoproxil is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor6 alternatives in D1
01
Doravirine
Brand: PIFELTRO
$60.95Lowest NADAC
0Generic mfrs
$121.3MCY24 Part D spend
Compare →
02
Efavirenz
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$1.37Lowest NADAC
5Generic mfrs
$5.8MCY24 Part D spend
Compare →
03
Efavirenz, Emtricitabine and Tenofovir Disoproxil
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$1.31Lowest NADAC
6Generic mfrs
CY24 Part D spend
Compare →
04
Efavirenz, Lamivudine and Tenofovir Disoproxil
Brand: SYMFI
Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →
05
Etravirine
Brand: Intelence
$7.77Lowest NADAC
3Generic mfrs
$35.4MCY24 Part D spend
Compare →
06
Nevirapine
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
$0.144Lowest NADAC
7Generic mfrs
$2.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.